



## **Precision BioSciences to Present at Upcoming H.C. Wainwright 4th Annual Hepatitis B Virus Conference**

October 23, 2023 at 7:00 AM EDT

DURHAM, N.C.--(BUSINESS WIRE)--Oct. 23, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop *in vivo* gene editing therapies for sophisticated gene edits, including gene insertion, excision, and elimination, today announced that the Company will present at the H.C. Wainwright 4<sup>th</sup> Annual Hepatitis B Virus (HBV) Virtual Conference taking place October 25, 2023.

### **Details for the virtual fireside chat are as follows:**

Date: Wednesday, October 25, 2023

Time: 9:30 AM ET

The fireside chat will be available via a live webcast accessible on Precision's website in the Investors section under Events & Presentations on October 25, 2023: <https://investor.precisionbiosciences.com/events-and-presentations>. An archived replay will be available for approximately 30 days following the event.

### **About Precision BioSciences, Inc.**

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline is comprised of *in vivo* gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit [www.precisionbiosciences.com](http://www.precisionbiosciences.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20231023532015/en/): <https://www.businesswire.com/news/home/20231023532015/en/>

### **Investor and Media Contact:**

Mei Burris

Senior Director of Finance and Corporate Controller

[Mei.Burris@precisionbiosciences.com](mailto:Mei.Burris@precisionbiosciences.com)

Source: Precision BioSciences, Inc.